CRDF (Cardiff Oncology) Tariff Resilience Score: 8/10 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
26 GF Score
Price $0.85
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Tariff Resilience Score?

Cardiff Oncology CRDF -1.48% 26 Tariff Resilience Score is 8 as of Jul. 23, 2026. GuruFocus rates CRDF with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, Cardiff Oncology ranks better than 98.69% on this metric.

Cardiff Oncology has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Cardiff Oncology has Cardiff Oncology's focus on biotech and R&D limits direct tariff exposure. Global supply chain for research materials is a minor risk, but strong IP and niche market reduce vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cardiff Oncology might have Highly Resilient.

Cardiff Oncology  (NAS:CRDF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cardiff Oncology Tariff Resilience Score Related Terms

CRDF vs MAIA, TELO, OSTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Cardiff Oncology's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Tariff Resilience Score falls into.


CRDF
26GF Score
Cardiff Oncology Inc CRDF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Cardiff Oncology (CRDF) has a Tariff Resilience Score of 8 as of Jul. 23, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cardiff Oncology ranks #18 out of 1370 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Cardiff Oncology's Tariff Resilience Score too high?
Cardiff Oncology's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Cardiff Oncology's value of 8 is 100% above this industry median. Based on the distribution chart, Cardiff Oncology ranks #18 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Tariff Resilience Score compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #18 out of 1370 companies for Tariff Resilience Score. This places Cardiff Oncology in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Cardiff Oncology's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Cardiff Oncology's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Tariff Resilience Score is 8 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score

Get the complete analysis for CRDF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price